The hemp-derived CBD industry is once again caught between a rock and a hard place. Recent positive actions by the FDA are now shaded by the DEA’s potentially disastrous rulemaking.
In this series of articles, Aaron Green sits down and interviews a number of industry executives leading manufacturing and extraction companies. In Part 5, Green sits down with Kristen Suchanec, VP of Production at Island to hear about how she got involved in the industry and how she sees the future of cannabis as a consumer packaged good.
In the 1st episode of the 2020 Cannabis Quality Virtual Conference, check out “Cannabis Market Trends & Consumer Insights” and “The New Normal: How Coronavirus Has and Will Affect the Cannabis Market”
Leafreport conducted independent lab testing on 22 different CBD-infused beverages and found a lot of inconsistencies with the actual amount of CBD found in the beverage and what the product’s label claimed.
In this op-ed, Visco calls on the Pennsylvania Governor to create sensible reform, with social equity and bipartisanship in mind.
In this series of articles, Aaron Green sits down and interviews a number of industry executives leading manufacturing and extraction companies. In Part 4, Green sits down with Michael Schimelpfenig, Head of R&D and BHO extraction manager at Bear Extraction House to hear about how he got involved in the industry and how he handles some of the day to day challenges.
Direct-to-consumer marketing can prove to be a valuable tool for hemp and CBD companies with less restrictions and a wider reach.
A number of class action lawsuits against CBD companies are hitting roadblocks. Federal judges want the FDA to complete their rulemaking before hearing a lot of these cases.
In this series of articles, Aaron Green sits down and interviews a number of industry executives leading manufacturing and extraction companies. In Part 3, Green sits down with Joaquin Rodriguez, chief operations officer at GenX Biotech to hear about product development and some of the challenges presently facing the industry.
Attorney General William Barr is accused of investigating the MedMen/PharmaCann merger based on his disdain for the cannabis industry. The implications of it could be far-reaching and long lasting.